It is time to expand the fatty liver disease community of practice

Abstract

CONFLICTS OF INTEREST Jeffrey V. Lazarus acknowledges grants and speaker fees from AbbVie, Gilead Sciences, MSD, and Roche Diagnostics to his institution, speaker fees from Intercept, Janssen, Novo Nordisk, and ViiV, and consulting fees from Novavax, outside of this work. Zobair M. Younossi acknowledges consulting fees from Quest, Abbott, Astra Zeneca, Bristol-Myers Squibb, Gilead Sciences, Intercept, Madridgal, Merck, Novo Nordisk, and Siemens Healthineers, outside of this work. Alina M. Allen acknowledges grant support to her institution from Novo Nordisk, Pfizer, and Target Pharma and advisory board participation for Novo Nordisk, outside of this work. Christopher J. Kopka has no conflicts of interest to disclose.

The Evolution in Non-Alcoholic Fatty Liver Disease Patients’ Profile and the Associated Sustainable Challenges: A Multidisciplinary Perspective

“…Gaining a precise understanding of the evolving epidemiology of NAFLD on a global scale presents challenges due to the lack of access to high-quality data, particularly in regions such as most African countries. Epidemiological investigations into NAFLD are frequently from a North American perspective, which complicates the global picture [ 32 ].…”

A global action agenda for turning the tide on fatty liver disease

“…There is growing clarity that more talent is needed to address the overall increasing burden of fatty liver disease. [50] Unsurprisingly, the panelists called for a strategic approach to expand the fatty liver disease community of practice (priority 6.6), which will both broaden and deepen the expertise and talent within the community. As the community of practice expands, the panelists also advocated for nurturing the next generation of both clinical and public health leaders (priority 6.3) and convening multidisciplinary experts to enact these priorities at all levels (priority 6.4).…”